Trump may be mystery patient in odd case of 79yo getting experimental obesity drug
Summary
A single 79-year-old patient was given early access to Eli Lilly’s experimental obesity drug retatrutide through the FDA’s compassionate use program. Reports suggest this patient may be President Donald Trump, who has obesity-related health conditions, though officials have not confirmed this.Key Facts
- Eli Lilly’s retatrutide is an experimental drug targeting hormones related to obesity, diabetes, and sleep apnea.
- The drug is currently in late-stage trials and has shown significant weight loss results similar to weight-loss surgery.
- Only one patient, aged 79, was granted early access to the drug through the FDA’s expanded access program.
- This patient reportedly has refractory obesity, obstructive sleep apnea, and pulmonary hypertension (high lung blood pressure).
- The access request was made in April by a senior NIH clinician on behalf of this patient.
- The patient previously used tirzepatide, another hormone-targeting obesity drug, with only moderate success.
- Neither the White House nor the Department of Health and Human Services confirmed if President Trump is the patient.
- Experts find it unusual that only one patient would get access to this drug under compassionate use for common conditions.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.